Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma has reported positive developments in their first quarter of 2024, including promising trial results for their chronic hepatitis B treatments and a solid financial position extending their cash runway into Q2 2026. The company is set to present important end-of-treatment data at the EASL Congress in June, highlighting the advances in their imdusiran trials. Additionally, Arbutus has made progress in a patent infringement lawsuit, with a court date set for April 2025 against Moderna.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
